Patenting and licensing inventions can have numerous benefits for scientists and their research programs. One can derive a great deal of personal satisfaction from knowing that their work may have direct applications toward relieving illness and suffering. One’s efforts can be widely recognized if developed into a commercial product. Collaboration and intellectual exchange with the biotechnology and pharmaceutical partners may result in financial sponsorship of research endeavors. Inventor/scientists receive a share of the royalties paid to OSU in exchange for a license which can further serve to incentivize research activity.
Category Archives: FAQ
Why Protect Intellectual Property?
Patent protection provides incentive for industry to license technologies from OSU. A patent gives OSU (to whom you have assigned your invention) the right to exclude others from practicing an invention for twenty years from the date of filing the application. That may seem like a long time until you consider the thousands of hours and millions of dollars it takes to develop, test, manufacture, and market a product before it is ever made available to the public. Patents are a company’s lifeblood. They offer exclusivity which reduces a company’s risk that it will be scooped during product research and development. In addition, the exclusivity gives a firm time to recoup its investment in a new product by acting as a barrier to the entry of competitors into the market.
Broad patent protection for a technology is not always appropriate or necessary. In some cases, trademark licensing or copyrights are adequate protection. Moreover, some technologies (e.g. cell lines and antibodies) can be licensed as research materials without patent protection.
Why is such a fuss made over CDA’s and MTA’s?
CDA’s and MTA’s are often the first step in maintaining IP rights and ensuring that your research results are not misappropriated by others.
Why do research institutions care about patents?
- In order to develop research results and move them into the commercial realm, IP protection must be in place to enable companies to retain exclusivity in the marketplace.
- This is especially important in the pharma and biotech industries where drug development takes several hundred million dollars and a decade or more.
- Companies must be able to recoup their investments in the technologies.
- See practical applications arise from lab research; improve quality of life.
- Federal law (Bayh-Dole Act) requires that results from federally funded research be developed to benefit taxpayers.
- Attract and retain top faculty.
- Revenues (shared with inventors).
- Economic Development for the state.
- Generates income to promote and support teaching and research.
Who signs MTA’s?
TCO. The only people at OSU authorized to sign these documents are the Vice President for Technology Commercialization and the Director of the Technology Commercialization and Knowledge Transfer office.
Who is an inventor?
An inventor is one who conceives a definite and permanent idea of an operative invention, including every feature of the subject matter to be patented.
- NOT AN INVENTOR – A person who:
- contributes to an obvious element of the invention
- merely suggests an idea
- simply follows instruction
- explains how or why an invention works
- adopts information derived from another
- JOINT INVENTION
- need not have physically worked together or at the same time
- need not make an equal contribution
- need not contribute to the subject matter of every claim
An inventor is one who conceives a definite and permanent idea of an operative invention, including every feature of the subject matter to be patented.
A patent application must name the correct inventors. Although you may want to include all collaborators, technicians, students, etc on a patent application, it may not be the best thing for the patent. You can always opt to recognize contributors who are not inventors by sharing licensing revenues with them. Incorrect inventorship can invalidate a patent. Inventorship is a legal determination that we ask our patent attorneys to make.
When should I call TCO about potentially patentable research?
As soon as possible. Waiting until the last minute before a publication or presentation can mean the loss of patent rights outside the US.
When is the best time to call TCO?
- The earlier the better… Even if you are not sure that you have an invention, please give us a call. We can help figure it out.
- The moment you learn that an MTA or CDA is needed…
- At the point of submitting a manuscript or abstract…
- Before giving a seminar…
- Before a public disclosure…
When do I need to do a CDA?
- Confidential Information (CI) about OSU IP is to be disclosed to someone outside the University.
- A company is willing to pay you for specific know-how.
- Company/institution wants to disclose CI to you for a specific purpose.
- When not already covered by confidentiality terms in an existing research contract, grant, or sponsored research agreement.
- When submitting reports/research results to company sponsors.
When do I need an MTA?
- When you receive a request for Material from outside OSU.
- When you are obtaining Material from outside OSU.
- When you are bringing material to OSU from outside e.g. when you migrate to OSU from another institution.
- When you leave OSU to work at another institution and wish to take materials with you.
